Sun Links With Israeli Institute As Part of Specialty Push
This article was originally published in PharmAsia News
Executive Summary
As Sun Pharma up-sizes its global business via the Ranbaxy buyout, the company is not losing sight of leads that could help it transform into a specialty drug maker. In its most recent move, Sun has struck a deal with an Israeli technology institute to jointly develop novel anticancer candidates.